Cliff Asness's IONS Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 18,762 shares of Ionis Pharmaceuticals, Inc. (IONS) worth $1.48 M, representing 0.00% of the portfolio. First purchased in 2015-Q4, this long-term strategic position has been held for 27 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in IONS, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2016, adding 1.47 M shares. Largest reduction occurred in Q3 2016, reducing 1.45 M shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Ionis Pharmaceuticals (IONS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ionis Pharmaceuticals (IONS) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +11,947 | Add 175.30% | 18,762 | $78.74 |
| Q3 2025 | +6,815 | New Buy | 6,815 | $64.38 |
| Q1 2024 | -4,300 | Sold Out | 0 | $0.00 |
| Q4 2023 | +4,300 | New Buy | 4,300 | $49.84 |
| Q1 2023 | -7,569 | Sold Out | 0 | $0.00 |
| Q4 2022 | -141 | Reduce 1.83% | 7,569 | $37.26 |
| Q3 2022 | +7,710 | New Buy | 7,710 | $44.23 |
| Q3 2021 | -13,434 | Sold Out | 0 | $0.00 |
| Q2 2021 | +13,434 | New Buy | 13,434 | $39.30 |
| Q3 2020 | -4,391 | Sold Out | 0 | $0.00 |
| Q2 2020 | -1,514 | Reduce 25.64% | 4,391 | $58.98 |
| Q1 2020 | -8,236 | Reduce 58.24% | 5,905 | $47.25 |
| Q4 2019 | -10,652 | Reduce 42.96% | 14,141 | $60.25 |
| Q3 2019 | -479,149 | Reduce 95.08% | 24,793 | $59.90 |
| Q2 2019 | +92,068 | Add 22.35% | 503,942 | $64.27 |
| Q1 2019 | +402,227 | Add 4169.45% | 411,874 | $80.18 |
| Q4 2018 | -2,959 | Reduce 23.47% | 9,647 | $54.11 |
| Q3 2018 | -4,835 | Reduce 27.72% | 12,606 | $51.56 |
| Q2 2018 | +27 | Add 0.16% | 17,441 | $41.68 |
| Q1 2018 | -813 | Reduce 4.46% | 17,414 | $44.10 |
| Q4 2017 | +370 | Add 2.07% | 18,227 | $50.31 |
| Q3 2017 | +17,857 | New Buy | 17,857 | $50.68 |
| Q4 2016 | -407,582 | Sold Out | 0 | $0.00 |
| Q3 2016 | -1.45 M | Reduce 78.07% | 407,582 | $36.64 |
| Q2 2016 | +1.47 M | Add 372.55% | 1.86 M | $23.29 |
| Q1 2016 | -220,851 | Reduce 35.96% | 393,235 | $40.50 |
| Q4 2015 | +614,086 | New Buy | 614,086 | $61.93 |
Cliff Asness's Ionis Pharmaceuticals Investment FAQs
Cliff Asness first purchased Ionis Pharmaceuticals, Inc. (IONS) in Q4 2015, acquiring 614,086 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Ionis Pharmaceuticals, Inc. (IONS) for 27 quarters since Q4 2015.
Cliff Asness's largest addition to Ionis Pharmaceuticals, Inc. (IONS) was in Q2 2016, adding 1,858,239 shares worth $43.28 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 18,762 shares of Ionis Pharmaceuticals, Inc. (IONS), valued at approximately $1.48 M.
As of the Q4 2025 filing, Ionis Pharmaceuticals, Inc. (IONS) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Ionis Pharmaceuticals, Inc. (IONS) was 1,858,239 shares, as reported at the end of Q2 2016.